FDA
-
-
-
-
-
-
-
Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026
-
-
-
-
-
-
-
Kamada receives FDA approval for Houston plasma collection center
-
-
-
-
-
-
-
Kamada Expects Third Plasma Collection Site To Support Its Hyper-Immune Plasma Needs And Add Up To $10M In Annual Revenue At Full Capacity
-
-
-
-
-
-
-
Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025
-
-
-
-
-
-
-
Kamada to Present at the Stifel 2024 Healthcare Conference
-
-
-
-
-
-
-
Kamada Issues 2024 CEO Letter to Shareholders
-
-
-
-
-
-
-
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

